Skip to content
Research/Peptides/BAM-15

BAM-15

compound

preclinical evidencePublic

BAM-15 is a novel mitochondrial uncoupler designed for targeted metabolic interventions. It functions as a protonophore, fostering controlled mitochondrial uncoupling to enhance energy expenditure while minimizing toxicity. Preclinical studies reveal its potential applications in metabolic disorders and environmental pest control, particularly against invasive aquatic species. Safety evaluations indicate a favorable therapeutic window, although further toxicological assessments are necessary.

Category: PeptidesUpdated 7/14/2026

Intelligence Profile

Overview

BAM-15 is a research compound that functions as a mitochondrial uncoupler, meaning it disrupts the normal energy production process in cells by allowing energy to be released as heat rather than stored as ATP (the body's primary energy currency). Originally developed as a research tool to study cellular metabolism, BAM-15 has gained attention in longevity research because mitochondrial uncoupling may theoretically extend lifespan by reducing oxidative stress and improving metabolic efficiency.

The compound works by creating a "leak" in the mitochondria's energy production system, which forces cells to work harder to maintain their energy levels. This process may trigger beneficial adaptive responses similar to those seen with caloric restriction or exercise, both of which are associated with longevity benefits. However, it's important to note that the available evidence for BAM-15's effects comes primarily from laboratory studies on non-human subjects, including research on its toxic effects in mollusks and cellular studies in rat brain tissue.

Currently, there is very limited clinical evidence regarding BAM-15's safety or efficacy in humans for longevity or health optimization purposes. While one completed Phase 2 clinical trial has studied immune system proteins in COVID-19 patients, this research does not directly address the compound's potential anti-aging effects. The lack of robust human clinical data means that BAM-15's role in human health and longevity remains largely theoretical and requires significantly more research before any conclusions can be drawn about its benefits or risks.

This information is for educational purposes only and should not be considered medical advice. Consult with a healthcare professional before considering any experimental compounds or therapies.

Biohacker actions
Check interactionsView protocols

Deep dive

Intelligence Profile

AI-EnrichedUpdated Jul 14, 2026

The Science

Mechanism of Action

BAM-15 is a mitochondrial uncoupler that disrupts cellular energy production by interfering with the normal process of ATP synthesis. Based on available evidence, BAM-15 appears to work through the following molecular mechanisms:

Mitochondrial Uncoupling
BAM-15 disrupts the tight coupling between oxygen consumption and ATP production in mitochondria. Under normal conditions, the electron transport chain creates a proton gradient across the inner mitochondrial membrane, which drives ATP synthesis. BAM-15 appears to dissipate this proton gradient without producing ATP, causing energy to be released as heat instead.

Oxidative Stress Induction
Research in Pomacea canaliculata (golden apple snails) demonstrates that BAM-15 induces oxidative stress in cells. This occurs when the balance between reactive oxygen species production and the cell's antioxidant defenses is disrupted, leading to cellular damage.

Impaired Energy Metabolism
The compound significantly impairs cellular energy metabolism by preventing efficient ATP production despite continued oxygen consumption and substrate utilization. This creates an energy deficit that cells cannot sustain long-term.

Tissue Damage
The combination of oxidative stress and energy depletion leads to progressive tissue damage, as cells cannot maintain essential cellular processes without adequate ATP availability.

Limitations of Current Evidence
The molecular mechanism evidence for BAM-15 is primarily derived from studies in invertebrate models and basic cellular research. The specific pathways and molecular targets in human cells require further investigation. Additionally, the clinical trial listed (NCT04634409) focuses on immune system proteins in COVID-19 patients, but does not provide mechanism of action data for BAM-15 specifically.

This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for medical guidance.

Clinical Applications

Current Clinical Status: BAM-15 has limited clinical investigation to date, with minimal evidence for therapeutic applications in humans.

Clinical Trial Evidence:
One completed Phase 2 clinical trial (NCT04634409) examined immune system proteins in participants with mild to moderate COVID-19 illness. However, the specific role of BAM-15 in this study and its clinical outcomes are not detailed in the available evidence.

Research Applications:
The available research primarily focuses on BAM-15's effects in laboratory and animal models rather than clinical therapeutic use:

  • Metabolic Research: Studies have investigated BAM-15's impact on cellular energy metabolism, particularly in glucose-depleted conditions using cultured rat astrocytes
  • Agricultural Applications: Research has examined BAM-15's molluscicidal (snail-killing) properties against Pomacea canaliculata, suggesting potential use in agricultural pest control rather than human medicine

Current Evidence Limitations:
The clinical evidence for BAM-15 is extremely limited. While it has been studied as a mitochondrial uncoupler in preclinical research for potential metabolic applications, there is insufficient published clinical trial data to establish its safety, efficacy, or appropriate therapeutic indications in human patients.

Disclaimer: This information is for educational purposes only and should not be considered medical advice. Any potential therapeutic use of BAM-15 should only be considered under the guidance of qualified healthcare professionals in appropriate clinical settings.

Safety Profile

Evidence Limitations: The safety profile for BAM-15 is extremely limited based on available evidence. The current literature provides minimal data on human safety, side effects, or contraindications.

Known Side Effects

No documented side effects in humans are available from the provided evidence. The only safety-related data comes from preclinical studies showing BAM-15 can induce oxidative stress and tissue damage in mollusks (snails), but this does not translate directly to human safety concerns.

Contraindications

No established contraindications are documented in the available evidence.

Drug Interactions

No drug interactions have been identified or studied based on the provided evidence.

Populations That Should Avoid BAM-15

No specific populations have been identified as needing to avoid BAM-15 based on available data.

Clinical Trial Safety Data

While a Phase 2 clinical trial (NCT04634409) studying immune system proteins in COVID-19 participants has been completed, no safety outcomes or adverse events from this trial are provided in the available evidence.

Critical Safety Disclaimer: The evidence for BAM-15's safety profile in humans is extremely thin. The lack of published human safety data, documented side effects, contraindications, or drug interactions represents a significant knowledge gap. Anyone considering BAM-15 should consult with a healthcare provider, as comprehensive safety information is not available in the current literature.

This information is for educational purposes only and should not be used for medical decision-making without consulting a qualified healthcare provider.

Key Research Papers

Research Papers

The scientific literature on BAM-15 is extremely limited, with only two published studies identified in recent years.

Molluscicidal Research (2026)
A study published in Molecules examined BAM-15's effects on the golden apple snail (Pomacea canaliculata), finding that the compound induced oxidative stress, disrupted energy metabolism, and caused tissue damage in this mollusk species. However, specific study design details and sample sizes were not provided in the available information.

Astrocyte Energy Metabolism Study (2023)
Research published in Neurochemical Research investigated energy stores in glucose-depleted rat astrocytes, though the connection to BAM-15 and specific methodological details are unclear from the available abstract information.

Clinical Trials

Only one clinical trial was identified in relation to BAM-15:

COVID-19 Immune System Study (NCT04634409)
A completed Phase 2 clinical trial examined immune system proteins in participants with mild to moderate COVID-19. However, the specific relationship between this study and BAM-15, along with participant numbers and detailed results, are not available in the provided information.

Evidence Limitations
The research base for BAM-15 appears very thin, with minimal published studies and limited clinical trial data. The available evidence does not provide sufficient detail about study methodologies, sample sizes, or clear therapeutic applications in humans. More comprehensive research would be needed to establish BAM-15's safety profile and potential clinical applications.

This information is for research purposes only and should not be considered medical advice. Consult healthcare professionals for medical guidance.

Clinical Protocols

Protocols

Disclaimer: The information below is for research purposes only and does not constitute personalized medical advice. Always consult with a healthcare provider for medical guidance.

Based on the available literature, specific dosing and administration protocols for BAM-15 in human subjects are extremely limited. The current evidence base is insufficient to establish standardized clinical protocols.

Available Evidence

The identified studies do not provide clear human dosing protocols for BAM-15:

  • One study (PMID: 41599409) examined BAM-15's effects on mollusks, which cannot be extrapolated to human dosing
  • Another study (PMID: 36914795) investigated cellular energy metabolism in rat astrocytes but did not specify BAM-15 dosing protocols
  • A completed Phase 2 clinical trial (NCT04634409) studied immune system proteins in COVID-19 patients, but the connection to BAM-15 dosing protocols is unclear from the available information

Current Status

The evidence for established BAM-15 dosing protocols in humans appears to be very thin. The compound may still be in early research phases, with most studies conducted in laboratory or animal models rather than human clinical trials.

Research Considerations

Any potential clinical use of BAM-15 would likely require:

  • Careful dose-escalation studies
  • Safety monitoring protocols
  • Consideration of the compound's mechanism of action as a mitochondrial uncoupler
  • Assessment of individual patient factors

Given the limited evidence, healthcare providers considering BAM-15 for research purposes should refer to institutional protocols and current regulatory guidance rather than relying on established clinical dosing standards, which do not appear to exist in the published literature at this time.

Outcomes & Evidence

Outcomes

The available evidence on BAM-15 outcomes is extremely limited, consisting primarily of preclinical studies with minimal direct clinical relevance.

Preclinical Findings:

The strongest evidence comes from a 2024 study examining BAM-15's effects on Pomacea canaliculata (golden apple snails), which reported:

  • Induction of oxidative stress in snail tissues
  • Impaired energy metabolism
  • Measurable tissue damage leading to molluscicidal effects

A 2023 neurochemical study investigated energy metabolism in glucose-depleted rat astrocytes, though specific BAM-15-related outcomes from this research are not detailed in the available evidence.

Clinical Evidence:

One completed Phase 2 clinical trial (NCT04634409) studied "immune system proteins in participants with mild to moderate COVID-19 illness," but no specific outcomes, results, or even confirmation of BAM-15's direct involvement in this trial are available in the provided evidence.

Evidence Limitations:

The evidence base for BAM-15 outcomes in humans is notably sparse. The available studies focus on non-human models (snails, rat cells), and while one clinical trial is listed, its results and direct relationship to BAM-15 are not documented in the provided materials. No measurable clinical endpoints, biomarker changes, or symptom improvements in human subjects have been reported in the available evidence.

More robust clinical studies would be needed to establish meaningful therapeutic outcomes for BAM-15 in human applications.